L'intérêt à découvert pour Ascentage Pharma Group donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Ascentage Pharma Group. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Ascentage Pharma Group (NASDAQ:AAPG) Stock, Rapport sur les intérêts à découvert

Ascentage Pharma Group

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group International

ASCENTAGE PHARMA GROUP INTL DS

<h3>Gainers</h3>
<ul>
<li>BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) shares increased by 13.5% to $2.6 during Wednesday's after-market session. The company's market cap stands at $184.6 million. </li>
<li>Euro Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) shares increased by 9.98% to $1.22. The market value of their outstanding shares is at $9.4 million. </li>
<li>Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) shares increased by 7.28% to $3.24. The market value of their outstanding shares is at $174.7 million. </li>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock moved upwards by 6.66% to $0.28. The market value of their outstanding shares is at $12.8 million. </li>
<li>Toppoint Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPP#AMEX">TOPP</a>) stock increased by 6.49% to $1.64. The market value of their outstanding shares is at $28.7 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares increased by 6.21% to $0.59. The company's market cap stands at $8.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares decreased by 14.9% to $23.73 during Wednesday's after-market session. The market value of their outstanding shares is at $313.1 million. As per the press release, Q2 earnings came out today. </li>
<li>Palladyne AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) stock fell 7.98% to $5.77. The company's market cap stands at $203.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLWT

PDYN

PITA

SLND

TOPP

8 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) shares rose 5.3% to $19.0 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out today. </li>
<li>Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) stock increased by 5.21% to $2.22. The market value of their outstanding shares is at $234.6 million. </li>
<li>Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) shares increased by 4.95% to $2.54. The company's market cap stands at $190.1 million. </li>
<li>Cheetah Mobile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMCM#NYSE">CMCM</a>) shares increased by 4.73% to $4.42. The market value of their outstanding shares is at $132.0 million. </li>
<li>Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) shares rose 4.56% to $8.7. The company's market cap stands at $393.6 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock moved upwards by 4.52% to $0.36. The company's market cap stands at $10.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) shares declined by 12.4% to $3.09 during Wednesday's after-market session. The market value of their outstanding shares is at $281.0 million. </li>
<li>PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) shares decreased by 9.73% to $16.53. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock decreased by 8.48% to $19.01. The company's market cap stands at $351.0 million. As per the press release, FY earnings came out 2 days ago. </li>
<li>Iveda Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock declined by 7.73% to $2.39. The market value of their outstanding shares is at $6.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMBM

CMCM

GRRR

IVDA

MITK

Penguin Solutions, Inc. - Ordinary Shares

PENG

RMNI

10 Information Technology Stocks Moving In Wednesday's After-Market Session

Earnings

News

AIRE

reAlpha Tech 2024 EPS From Continuing Operations $(0.17), Sales $0.95M

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock moved upwards by 15.2% to $0.14 during Wednesday's after-market session. The company's market cap stands at $7.0 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares rose 9.55% to $0.01. The company's market cap stands at $2.3 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) stock moved upwards by 7.29% to $24.9. The company's market cap stands at $29.0 million. </li>
<li>ECARX Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) shares rose 5.77% to $1.19. The company's market cap stands at $441.1 million. </li>
<li>Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) stock increased by 5.07% to $0.26. The company's market cap stands at $4.2 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares rose 4.95% to $0.2. The market value of their outstanding shares is at $79.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) stock decreased by 23.9% to $189.89 during Wednesday's after-market session. The company's market cap stands at $3.5 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) stock fell 12.61% to $29.47. The company's market cap stands at $3.7 billion. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock decreased by 10.96% to $1.3. The market value of their outstanding shares is at $45.6 million. </li>
<li>Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) stock declined by 10.44% to $72.99. The company's market cap stands at $4.0 billion. </li>
<li>Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) stock fell 10.1% to $53.07. The market value of their outstanding shares is at $8.0 billion. </li>
<li>Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) shares decreased by 9.78% to $50.0. The company's market cap stands at $4.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EVTV

FIVE

HOUR

LXEH

QVCGA

URBN

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 151.6% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $4.1 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 32.6% to $1.83. The company's market cap stands at $2.6 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares moved upwards by 32.16% to $0.39. The company's market cap stands at $3.3 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock rose 12.66% to $0.23. The company's market cap stands at $6.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock rose 10.2% to $0.22. The market value of their outstanding shares is at $4.7 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 9.92% to $0.69. The market value of their outstanding shares is at $100.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 21.1% to $0.7 during Wednesday's after-market session. The market value of their outstanding shares is at $10.9 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares declined by 16.27% to $32.0. The company's market cap stands at $1.9 billion. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares decreased by 13.73% to $6.85. The company's market cap stands at $1.0 billion. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock decreased by 12.86% to $1.22. The company's market cap stands at $226.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 12.08% to $0.7. The market value of their outstanding shares is at $50.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 11.04% to $1.37. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

APVO

BDRX

BDSX

BIAF

CERS

CTOR

GNPX

KLTO

OGEN

PTIX

TWST

12 Health Care Stocks Moving In Wednesday's After-Market Session

13 analysts have expressed a variety of opinions on Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $166.85, along with a high estimate of $181.00 and a low estimate of $152.00. Observing a downward trend, the current average is 1.94% lower than the prior average price target of $170.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627702_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Johnson &amp; Johnson by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$171.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Neutral</td>
<td>$166.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$166.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$163.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$155.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$169.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$165.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Johnson &amp; Johnson's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Discovering Johnson &amp; Johnson: A Closer Look</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 5.26%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Johnson &amp; Johnson's net margin excels beyond industry benchmarks, reaching 15.24%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Johnson &amp; Johnson's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.84% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.91%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Johnson &amp; Johnson adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 13 Analyst Ratings Have To Say About Johnson & Johnson

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bank of New York Mellon, revealing an average target of $93.06, a high estimate of $104.00, and a low estimate of $83.00. Observing a 4.48% increase, the current average has risen from the previous average price target of $89.07. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627694_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Bank of New York Mellon among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$87.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$96.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$104.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$83.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$93.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bank of New York Mellon. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bank of New York Mellon compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bank of New York Mellon's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bank of New York Mellon's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bank of New York Mellon analyst ratings.</a>
<h2>Unveiling the Story Behind Bank of New York Mellon</h2>
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of December 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.0 trillion in assets.
<h3>Understanding the Numbers: Bank of New York Mellon's Finances</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Bank of New York Mellon displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.84%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Bank of New York Mellon's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 23.74%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.03%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Bank of New York Mellon's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.27%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Bank of New York Mellon's debt-to-equity ratio is below the industry average at 0.85, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

16 Analysts Assess Bank of New York Mellon: What You Need To Know

5 analysts have expressed a variety of opinions on Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Spectrum Brands Holdings and provided 12-month price targets. The average target is $96.8, accompanied by a high estimate of $110.00 and a low estimate of $75.00. Experiencing a 2.02% decline, the current average is now lower than the previous average price target of $98.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627672_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Spectrum Brands Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$88.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Spectrum Brands Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Spectrum Brands Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Spectrum Brands Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Spectrum Brands Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SPB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Spectrum Brands Holdings analyst ratings.</a>
<h2>All You Need to Know About Spectrum Brands Holdings</h2>
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, and Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East &amp; Africa, Latin America, and Asia-Pacific.
<h3>Breaking Down Spectrum Brands Holdings's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Spectrum Brands Holdings showcased positive performance, achieving a revenue growth rate of 1.16% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Spectrum Brands Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.36%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.13%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.63%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Spectrum Brands Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 5 Analyst Projections For Spectrum Brands Holdings

Globe Life (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $136.44, a high estimate of $152.00, and a low estimate of $114.00. Witnessing a positive shift, the current average has risen by 3.56% from the previous average price target of $131.75.
<img src="https://www.benzinga.com/files/images/story/2025/1743627663_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Globe Life by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$152.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$126.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$141.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$114.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$132.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globe Life. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Globe Life compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Globe Life's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Globe Life's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Globe Life analyst ratings.</a>
<h2>Discovering Globe Life: A Closer Look</h2>
Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into three reportable segments: life insurance, supplemental health insurance and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.
<h3>Understanding the Numbers: Globe Life's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Globe Life's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.57% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Globe Life's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 17.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Globe Life's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 5.13%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.87%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.52, Globe Life adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Globe Life Stands With Analysts

During the last three months, 5 analysts shared their evaluations of SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.8, a high estimate of $99.00, and a low estimate of $80.00. Observing a 7.64% increase, the current average has risen from the previous average price target of $82.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627654_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of SEI Inv among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayna Kumar</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$81.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$90.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$99.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Rayna Kumar</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SEI Inv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of SEI Inv compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for SEI Inv's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SEI Inv's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SEI Inv analyst ratings.</a>
<h2>Delving into SEI Inv's Background</h2>
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $87 billion in assets under management. As of December 2024, SEI (including LSV) manages, administers, or advises about $1.6 trillion in assets.
<h3>Breaking Down SEI Inv's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: SEI Inv displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 14.92%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: SEI Inv's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 27.96%, the company may face hurdles in effective cost management.
Return on Equity (ROE): SEI Inv's ROE stands out, surpassing industry averages. With an impressive ROE of 6.76%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): SEI Inv's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.8% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: SEI Inv's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SEIC

5 Analysts Have This To Say About SEI Inv

In the preceding three months, 5 analysts have released ratings for Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Synovus Finl, presenting an average target of $60.3, a high estimate of $62.00, and a low estimate of $58.00. Observing a downward trend, the current average is 1.95% lower than the prior average price target of $61.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743627644_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Synovus Finl by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Benjamin Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$62.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$60.50</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.50</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Synovus Finl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Synovus Finl compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Synovus Finl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Synovus Finl's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SNV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Synovus Finl analyst ratings.</a>
<h2>Unveiling the Story Behind Synovus Finl</h2>
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products &amp; services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, &amp; international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
<h3>Synovus Finl: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Synovus Finl showcased positive performance, achieving a revenue growth rate of 18.81% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Synovus Finl's net margin excels beyond industry benchmarks, reaching 30.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.75%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Synovus Finl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.3% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Synovus Finl's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Synovus Finl's Future

In the current market session, Hillman Solns Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) price is at $8.99, after a 1.47% increase. However, over the past month, the stock decreased by 4.97%, and in the past year, by 11.69%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1743627617_0.png" alt="Past Year Chart" />

<h3>Evaluating Hillman Solns P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Hillman Solns has a better P/E ratio of 98.44 than the aggregate P/E ratio of 29.17 of the Machinery industry. Ideally, one might believe that Hillman Solns Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743627617_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

HLMN

P/E Ratio Insights for Hillman Solns

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) has outperformed the market over the past 5 years by 1.91% on an annualized basis producing an average annual return of 18.23%. Currently, UMB Financial has a market capitalization of $7.41 billion. 
Buying $100 In UMBF: If an investor had bought $100 of UMBF stock 5 years ago, it would be worth $234.76 today based on a price of $101.98 for UMBF at the time of writing.
<h3>UMB Financial's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743627613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

UMBF

Here's How Much $100 Invested In UMB Financial 5 Years Ago Would Be Worth Today

RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) reported fourth-quarter financial results after the market close on Wednesday. Shares are tumbling in reaction to a top- and bottom-line miss. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b44614910/rh-reports-fourth-quarter-and-fiscal-2024-results">of the report</a>.
Q4 Earnings: RH reported fourth-quarter revenue of $812.41 million, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $829.56 million, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
Total revenue was up 10% on a year-over-year basis as fourth-quarter demand jumped 17%. The company reported adjusted operating income of $92 million, up 38% year-over-year, and adjusted EBITDA margin of 17.1%. 
&#8220;The important work and substantial investments we've made over the past two years are now resulting in meaningful share gains and significant strategic separation, positioning the RH brand to expand its leadership position across the luxury home market over the next decade,&#8221; the company said in a letter to shareholders.
&#8220;While demand softened in mid-December after mortgage rates spiked and mortgage applications fell 22 percent post the Fed signaling rates would remain largely unchanged this year, RH Brand demand stabilized at up 19% in January.&#8221;
See Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44614042/jpmorgan-wells-fargo-morgan-stanley-bny-mellon-will-strike-a-cautious-tone-analysts"> JPMorgan, Wells Fargo, Morgan Stanley, BNY Mellon Will &#8216;Strike A Cautious Tone&#8217;: Analysts</a>
Outlook: RH expects first-quarter revenue growth of 12.5% to 13.5%. The company anticipates full-year 2025 revenue growth of 10% to 13%. 
RH said it plans to introduce a new RH Outdoor Sourcebook and new RH Interiors Sourcebook in 2025. The company also highlighted plans to launch a &#8220;significant&#8221; brand extension in the fall that it believes will &#8220;meaningfully expand the market size and share of the RH brand.&#8221;
RH also plans to open seven design galleries, two outdoor galleries and two new concept galleries throughout the year. 
RH executives will further discuss the quarter on a call with investors and analysts at 5 p.m. ET.
RH Price Action: <a href="http://benzinga.com/quote/rh">RH shares</a> were down 25.41% after-hours, trading at $186 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/ZHI+Qi">Helen89</a>/Shutterstock.

Guidance

After-Hours Center

RH Q4 Earnings: Shares Sink As Revenue, EPS Miss Expectations

Kenon Holdings 2024 Revenue $751M Up From $692M YoY

President Donald Trump on Wednesday unveiled a sweeping new trade offensive aimed at rebalancing America's trade relationships, calling it &#8220;our <a href="https://www.benzinga.com/topic/tariffs">Declaration of Economic Independence.&#8221;</a>
&#8220;April 2nd, 2025 will forever be remembered as the day American industry was reborn, the day America&#8217;s destiny was reclaimed,&#8221; Trump said.
The centerpiece of Trump's announcement is a new reciprocal tariff structure that will apply to imports from trading partners, set at half the tariff rate they impose on U.S. goods.
Trump called April 2 "one of the most important days in American history," likening the move to a declaration of economic independence. 
He stated previous administrations had "ripped off taxpayers for over 50 years" by allowing foreign nations to flood the U.S. with goods while blocking American exports.
<h2 class="wp-block-heading">How Will Reciprocal Tariffs Work?</h2>
While full reciprocity was floated, Trump said the plan would cap U.S. retaliation at 50% of what foreign nations charge. 
This includes non-monetary barriers — such as VAT taxes, product bans, subsidies, and technical restrictions — in tariff calculations.
"They manipulated their currencies, subsidized exports, stole our intellectual property, imposed exorbitant VAT taxes, and created filthy pollution havens," Trump said.
For instance, Japan, which he said imposes tariffs as high as 46% on some goods, would now face U.S. duties of around 24%. India's 52% rate would translate to a 26% U.S. tariff. 
"To all of the foreign presidents, prime ministers, kings, queens, ambassadors and everyone else who will soon be calling to ask for exemptions from these tariffs," he said, 
"I say terminate your own tariffs. Drop your barriers. Don't manipulate your currencies," Trump said.
<h2 class="wp-block-heading">New US Reciprocal Tariffs By Country</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td> </td>
<td>Tariffs Charged to the U.S.</td>
<td>New Discounted Reciprocal Tariffs</td>
</tr>
<tr>
<td>China</td>
<td>67%</td>
<td>34%</td>
</tr>
<tr>
<td>European Union</td>
<td>39%</td>
<td>20%</td>
</tr>
<tr>
<td>Vietnam</td>
<td>90%</td>
<td>46%</td>
</tr>
<tr>
<td>Taiwan</td>
<td>64%</td>
<td>32%</td>
</tr>
<tr>
<td>Japan</td>
<td>46%</td>
<td>24%</td>
</tr>
<tr>
<td>India</td>
<td>52%</td>
<td>26%</td>
</tr>
<tr>
<td>South Korea</td>
<td>50%</td>
<td>25%</td>
</tr>
<tr>
<td>Thailand</td>
<td>72%</td>
<td>36%</td>
</tr>
<tr>
<td>Switzerland</td>
<td>61%</td>
<td>31%</td>
</tr>
<tr>
<td>Indonesia</td>
<td>64%</td>
<td>32%</td>
</tr>
<tr>
<td>Malaysia</td>
<td>47%</td>
<td>24%</td>
</tr>
<tr>
<td>Cambodia</td>
<td>97%</td>
<td>49%</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>South Africa</td>
<td>60%</td>
<td>30%</td>
</tr>
<tr>
<td>Brazil</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>74%</td>
<td>37%</td>
</tr>
<tr>
<td>Singapore</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Israel</td>
<td>33%</td>
<td>17%</td>
</tr>
<tr>
<td>Philippines</td>
<td>34%</td>
<td>17%</td>
</tr>
<tr>
<td>Chile</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Australia</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Pakistan</td>
<td>58%</td>
<td>29%</td>
</tr>
<tr>
<td>Turkey</td>
<td>10%</td>
<td>10%</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>88%</td>
<td>44%</td>
</tr>
<tr>
<td>Colombia</td>
<td>10%</td>
<td>10%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44610548/trumps-auto-tariffs-could-crush-demand-blow-26-billion-hole-in-industry-profits">Trump&#8217;s Auto Tariffs Could Crush Demand, Blow $26 Billion Hole In Industry Profits</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Econ #s

Economics

Donald Trump Sets Reciprocal Tariffs On Key Trade Partners In Historic Policy Shock

The projects will be included in first quarter 2025 backlog.

Contracts

Southland Holdings Secures Two Water Resource Projects In The Southwest Totaling Approximately $97M

Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) has outperformed the market over the past 5 years by 11.36% on an annualized basis producing an average annual return of 27.67%. Currently, Energy Transfer has a market capitalization of $64.95 billion. 
Buying $100 In ET: If an investor had bought $100 of ET stock 5 years ago, it would be worth $341.70 today based on a price of $18.93 for ET at the time of writing.
<h3>Energy Transfer's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743626713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Energy Transfer 5 Years Ago Would Be Worth Today

Logistic Properties Of The Americas FY24 Revenue $43.8M Up From $39.4M YoY

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) has been one of the most volatile AI stocks this year. After surging nearly 400% in 2024, the stock has struggled in recent months, dropping 25% from its all-time high <a href="https://www.benzinga.com/quote/PLTR">reached in mid-February. </a>
What To Know: Palantir has benefited from growing demand for its AI-powered data analytics platforms, particularly among government agencies and large enterprises. The company's revenue growth remains strong, with management projecting a 36% increase in the first quarter. However, some analysts believe this estimate may be conservative, as Palantir has a track record of setting expectations lower to deliver consistent revenue beats.
Even with this growth, Palantir's stock price has been a point of concern. The stock currently trades at a price-to-sales (P/S) ratio of 77, a level that requires extreme revenue acceleration to justify. For comparison, most software companies trade between 10 and 20 times sales. At its current valuation, Palantir would need to triple its revenue annually to maintain its stock price, an unlikely scenario given its current growth trajectory.
Ai Outlook: The AI investment landscape is also shifting. While businesses continue to integrate AI solutions, spending trends are becoming more scrutinized. 
Investors who piled into Palantir during last year's AI boom are now questioning whether the company can sustain its momentum. If revenue growth falls short or macroeconomic headwinds intensify, Palantir's stock could see further downside.
Market Overview: Market-wide weakness in high-growth tech stocks has also weighed on Palantir. Other AI-related names, including C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) and Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), have seen similar pullbacks, reflecting broader concerns about valuations in the sector. While Palantir remains a leader in AI-driven analytics, its current stock price leaves little room for error.
The next few quarters may be crucial in determining whether Palantir can justify its high valuation. If the company continues to beat growth expectations and expand its commercial customer base, investor confidence may stabilize. However, if growth stalls or macroeconomic risks intensify, the stock could remain under pressure.
PLTR Price Action: Palantir shares closed up 3.27% at $87.45 at publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0402"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1024x536.png" alt="" class="wp-image-854115" style="width:343px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13-1536x804.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02154248/Screenshot-2025-04-02-at-15.42.13.png 1544w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44613907/tariff-shock-incoming-as-trump-prepares-sweeping-trade-duties-what-traders-need-to-know">Trump&#8217;s &#8216;Liberation Day&#8217; Tariff Reveal Set For 4 PM: What&#8217;s At Stake</a></li>
</ul>
Photo: Shutterstock.

Tech

PLTR

SNOW

Palantir Stock Drops As Valuation Concerns Grow: What You Need To Know (Updated)

IPOs

Press Releases

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering

Financing

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

General

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

Comments

Ascentage Pharma Group

Intérêt court

Ascentage Pharma Group (NASDAQ:AAPG) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL